Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

Madrigal Pharmaceuticals MDGL reported third-quarter 2024 loss of $4.92 per share, narrower than the Zacks Consensus Estimate ...

Madrigal Pharmaceuticals' Rezdiffra for NASH shows strong early demand, positioning the company as a market leader. Read why ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...

Sibold credited Rezdiffra's sales growth to the growing adoption of the treatment by prescribers, broader payer coverage for ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Q3 2024 Earnings Call Transcript October 31, 2024 Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Analysts expect Madrigal Pharmaceuticals to report an earnings per share (EPS) of $-7.09. The announcement from Madrigal Pharmaceuticals is eagerly anticipated, with investors seeking news of ...

Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives ...

Bill Sibold, Chief Executive Officer of Madrigal, stated, “This will be the first AASLD Liver Meeting following the approval of Rezdiffra earlier this year, and the entire NASH community feels ...